340B Snapshot
Read about the recent industry events affecting your program.
New Lawsuit AbbVie v. HRSA challenges 340B Patient Definition
Put on your seatbelt. The 340B space is about to get even more interesting. The newly filed AbbVie lawsuit against HRSA presents the inverse legal argument advanced in Genesis HealthCare Inc.
Evolving Manufacturer Claims Requirements as HRSA Signals a Potential New Rebate Pilot
New manufacturer communications indicate an important shift in how 340B-priced drugs may be accessed going forward. Letters issued by Eli Lilly and Company and Pfizer Inc. reflect an increased emphasis on claims-level data submission as a condition of 340B access.
New Manufacture Restrictions Emerge - Lilly’s New 340B In-House Claims Data Requirement
With the HRSA 340B Rebate Pilot temporarily on hold pending litigation, Eli Lilly and Company is expanding its efforts for 340B claims oversight.
340B Rebate Pilot Update – Legal Action Paused, Future Uncertain
With the HRSA 340B Rebate Pilot temporarily on hold pending litigation, Eli Lilly and Company is expanding its efforts for 340B claims oversight.
First Circuit Court Blocks HHS Request to Restart 340B Rebate Pilot
With the HRSA 340B Rebate Pilot temporarily on hold pending litigation, Eli Lilly and Company is expanding its efforts for 340B claims oversight.
HRSA Posts Announcement that the 340B Rebate Pilot Implementation is Paused
With the HRSA 340B Rebate Pilot temporarily on hold pending litigation, Eli Lilly and Company is expanding its efforts for 340B claims oversight.
Federal Judge Temporarily Blocks 340B Rebate Pilot Implementation
With the HRSA 340B Rebate Pilot temporarily on hold pending litigation, Eli Lilly and Company is expanding its efforts for 340B claims oversight.
HRSA Launches 340B Rebate Model Pilot Program to Test Alternative Pricing Approach
With the HRSA 340B Rebate Pilot temporarily on hold pending litigation, Eli Lilly and Company is expanding its efforts for 340B claims oversight.
HHS Advances 340B Rebate Guidance Amid Legal Developments
With the HRSA 340B Rebate Pilot temporarily on hold pending litigation, Eli Lilly and Company is expanding its efforts for 340B claims oversight.